Century Therapeutics (IPSC) Competitors $0.56 +0.02 (+4.19%) As of 02:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPSC vs. CHRS, BIOA, GNLX, CRBP, FBRX, DERM, FATE, PLX, IPHA, and TNXPShould you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Coherus Oncology (CHRS), BioAge Labs (BIOA), Genelux (GNLX), Corbus Pharmaceuticals (CRBP), Forte Biosciences (FBRX), Journey Medical (DERM), Fate Therapeutics (FATE), Protalix BioTherapeutics (PLX), Innate Pharma (IPHA), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry. Century Therapeutics vs. Its Competitors Coherus Oncology BioAge Labs Genelux Corbus Pharmaceuticals Forte Biosciences Journey Medical Fate Therapeutics Protalix BioTherapeutics Innate Pharma Tonix Pharmaceuticals Century Therapeutics (NASDAQ:IPSC) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability. Which has stronger earnings & valuation, IPSC or CHRS? Coherus Oncology has higher revenue and earnings than Century Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentury Therapeutics$6.59M7.41-$126.57M-$0.29-1.95Coherus Oncology$266.96M0.76$28.51M$1.551.13 Which has more risk & volatility, IPSC or CHRS? Century Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Do analysts prefer IPSC or CHRS? Century Therapeutics currently has a consensus target price of $3.75, suggesting a potential upside of 563.72%. Coherus Oncology has a consensus target price of $4.51, suggesting a potential upside of 157.12%. Given Century Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Century Therapeutics is more favorable than Coherus Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Century Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60Coherus Oncology 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Do institutionals and insiders have more ownership in IPSC or CHRS? 50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 5.0% of Century Therapeutics shares are owned by insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is IPSC or CHRS more profitable? Coherus Oncology has a net margin of 125.90% compared to Century Therapeutics' net margin of -19.10%. Coherus Oncology's return on equity of 0.00% beat Century Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Century Therapeutics-19.10% -11.53% -6.94% Coherus Oncology 125.90%N/A -34.85% Does the media refer more to IPSC or CHRS? In the previous week, Century Therapeutics had 2 more articles in the media than Coherus Oncology. MarketBeat recorded 3 mentions for Century Therapeutics and 1 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.67 beat Century Therapeutics' score of 0.19 indicating that Coherus Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Coherus Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCoherus Oncology beats Century Therapeutics on 9 of the 16 factors compared between the two stocks. Get Century Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPSC vs. The Competition Export to ExcelMetricCentury TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.81M$2.64B$6.17B$10.69BDividend YieldN/A57.79%5.72%4.83%P/E Ratio-1.9523.8029.4327.35Price / Sales7.41803.84589.84133.82Price / CashN/A27.2425.8230.35Price / Book0.305.4712.466.69Net Income-$126.57M$33.06M$3.32B$276.36M7 Day Performance2.75%1.53%2.28%0.88%1 Month Performance18.40%9.91%8.61%3.83%1 Year Performance-64.69%-2.89%61.86%36.51% Century Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPSCCentury Therapeutics2.7731 of 5 stars$0.57+4.2%$3.75+563.7%-66.1%$48.81M$6.59M-1.95170News CoverageAnalyst DowngradeCHRSCoherus Oncology4.1733 of 5 stars$1.73+3.6%$4.51+160.8%+86.9%$194.10M$266.96M1.12330BIOABioAge LabsN/A$5.50+2.8%N/AN/A$191.80MN/A0.00N/AGNLXGenelux0.8552 of 5 stars$5.25+3.6%$20.33+287.3%+108.0%$191.51M$10K-6.1010Gap UpCRBPCorbus Pharmaceuticals4.2245 of 5 stars$16.32+5.0%$45.43+178.4%+4.9%$190.45MN/A-3.4340News CoverageAnalyst ForecastGap UpFBRXForte Biosciences2.7975 of 5 stars$14.75-3.4%$68.00+361.0%+155.4%$189.85MN/A-0.915Analyst DowngradeShort Interest ↑DERMJourney Medical2.0188 of 5 stars$7.00-2.9%$12.17+73.8%+17.6%$189.69M$56.13M-18.4290FATEFate Therapeutics4.1224 of 5 stars$1.39-15.0%$3.30+137.4%-54.5%$188.56M$13.63M-0.96550Gap UpPLXProtalix BioTherapeutics2.1118 of 5 stars$2.45+3.8%$15.00+512.2%+70.6%$188.17M$61.95M-18.85200IPHAInnate Pharma2.1002 of 5 stars$1.93-4.9%$6.50+236.8%+6.4%$187.13M$21.77M0.00220TNXPTonix Pharmaceuticals2.8077 of 5 stars$20.06-5.3%$70.00+249.0%+3.4%$185.75M$10.09M-0.5150Short Interest ↑Gap Down Related Companies and Tools Related Companies CHRS Alternatives BIOA Alternatives GNLX Alternatives CRBP Alternatives FBRX Alternatives DERM Alternatives FATE Alternatives PLX Alternatives IPHA Alternatives TNXP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPSC) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
